<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01636908</url>
  </required_header>
  <id_info>
    <org_study_id>2011/128</org_study_id>
    <nct_id>NCT01636908</nct_id>
  </id_info>
  <brief_title>Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.</brief_title>
  <acronym>ICK</acronym>
  <official_title>Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine intratumoral concentration of kinase inhibitors&#xD;
      upon 2 weeks of treatment in tumor tissue of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be cohort-wise treated with clinically available kinase inhibitors for 2 weeks&#xD;
      prior to standard palliative treatment. Five patients will be included in each of eight drug&#xD;
      cohorts. Biopsies will be performed to determine intratumoral drug concentrations and to&#xD;
      compare tissue (phospho)proteomic and kinase activity profiles before and during therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>concentrations of intratumoral kinase inhibitors upon 2 weeks of treatment</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>kinase inhibitor concentrations in plasma, serum and PBMC's upon 2 weeks of treatment</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-dermal kinase inhibitor concentrations upon 2 weeks of treatment</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine per patient whether 2 weeks of treatment with kinase inhibitors induces significant change of phosphoproteomic profiles in tumor tissue</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine per patient whether 2 weeks of treatment with kinase inhibitors induces significant change of kinase activity in tumor tissue</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Cancer</condition>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Kinase inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg, twice daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>1250 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>100 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>800 mg once daily, oral use, 14 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>960 mg twice daily, oral use, 15-21 days</description>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tumor biopsy</intervention_name>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>skin biopsy (optional)</intervention_name>
    <arm_group_label>Kinase inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced solid malignancy&#xD;
&#xD;
          -  minimum age 18 years&#xD;
&#xD;
          -  indication for palliative treatment&#xD;
&#xD;
          -  measurable disease with at least one lesion accessable for biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiovascular conditions including congestive heartfailure NYHA class &gt;2&#xD;
&#xD;
          -  recent myocardial infarction or uncontrolled coronary artery disease&#xD;
&#xD;
          -  cardiac arrhythmias requiring anti-arrhythmic therapy&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
&#xD;
          -  uncontrolled infections&#xD;
&#xD;
          -  serious non-healing wound, ulcer or bone fracture&#xD;
&#xD;
          -  pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H.M.W. Verheul, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU Medical Center Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VUMedical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 5, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>M. Labots</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

